BMY.TO
BuyUnloved QualityAI neutralBristol-Myers Squibb Company · Healthcare · United States · $126.2B cap
CAD 22.62 -0.5% · close 26 Oct · scored 27 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on BMY.TO (Jun 2026), freeAs of 27 Oct 2026, MoatMap's StockRank for Bristol-Myers Squibb Company (BMY.TO) is 72/100, ranked against 24,000+ stocks in 35 markets (Quality 74, Value 69, Momentum 25, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Bristol-Myers Squibb maintains a broad portfolio in oncology and cardiovascular therapies, trading at undemanding valuation metrics. Nevertheless, recent officer share dispositions warrant prudence while the business manages patent expiration headwinds on legacy blockbusters.
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMY.TO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BMY.TO | Bristol-Myers Squibb Company(you) | $126.2B | 72 | Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $71.3B | 72 | Buy |
| 1GILD.MI | Gilead Sciences, Inc. | $178.7B | 79 | Buy |
| PFE | Pfizer Inc. | $171.2B | 83 | Strong Buy |
| AZN | AstraZeneca PLC | $266.0B | 69 | Buy |
| NVO | Novo Nordisk A/S | $172.3B | 83 | Strong Buy |
| GSK.L | GSK plc | $101.6B | 87 | Strong Buy |
| SAN.PA | Sanofi | $99.5B | 89 | Strong Buy |
| NVS | Novartis AG | $287.2B | 80 | Strong Buy |
| BIIB | Biogen Inc. | $37.0B | 74 | Buy |
Peer medians: ROE 2.7% · P/E 23.5x · Gross margin 53.5%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.